Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. reports developments across its orthopedic and spine medical technology portfolio. The company provides spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH Navigation System, for complex musculoskeletal conditions.
Recurring OFIX news includes quarterly results, guidance, product launches and commercial execution in Spine and Orthopedics. Company updates also cover pediatric limb reconstruction offerings such as FITBONE, planning software such as OrthoNext, the TRUELOK Elevate system, spine leadership realignment, distributor transitions, biologics activity and the discontinued M6 artificial disc product lines.
Orthofix Medical Inc (NASDAQ:OFIX) announced its participation in the virtual North American Spine Society (NASS) 2020 meeting from October 6-9, showcasing multiple clinical abstracts. The company emphasized its focus on building clinical evidence for its technologies, including the M6-C artificial cervical disc and Trinity ELITE Allograft. Key presentations highlighted clinical results and ongoing studies related to spine innovations, showcasing the potential benefits of their products in surgery and patient outcomes.
Orthofix Medical (NASDAQ:OFIX) has received FDA 510(k) clearance for its FIREBIRD SI Fusion System, which features innovative nanotechnology. This system, designed for stabilizing the sacroiliac joint during fusion, utilizes a 3D-printed titanium bone screw enhanced with a unique nano-surface. It aims to facilitate better recovery through a minimally invasive procedure, accommodating various patient anatomies. This announcement is part of Orthofix's strategy to present its advancements at the upcoming North American Spine Society annual meeting.